Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
European Journal of Cancer2018Vol. 101, pp. 160–164
Citations Over TimeTop 10% of 2018 papers
Alice Bernard‐Tessier, Capucine Baldini, Patricia Martín, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Andréa Varga, Rastilav Bahleda, Anas Gazzah, Jean‐Marie Michot, Vincent Ribrag, Jean‐Pierre Armand, Aurélien Marabelle, Jean‐Charles Soria, Christophe Massard
Related Papers
- Current and future applications of SPECT in clinical psychiatry.(1992)
- [Discontinuation of chronic treatment with lithium salts].(1992)
- Types Research of Discontinuation of a Crime(2007)
- → Accurate collection of reasons for treatment discontinuation to better define estimands in clinical trials(2022)